Table 1.
Summary Of Clinical Data Of RET-Inhibitors
| Trial | Study phase | RET Inhibitor | Pharmacodynamic | No | ORR (%) | PFS (Months) | OS (Months) | Grade ≥3 AEs (%) | Discontinuation Rate (%) |
|---|---|---|---|---|---|---|---|---|---|
| Drilon et al 201644 | II | Cabozantinib | Multi-kinase inhibitor | 26 | 28 | 5.5 | 9.9 | 69 | 8 |
| Yoh et al 2017 (LURET) | II | Vandetanib | Multi-kinase inhibitor | 19 | 53 | 4.7 | N/R | N/R | 11.1 |
| Lee et al, 201743 | II | Vandetanib | Multi-kinase inhibitor | 18 | 18 | 4.5 | 11.6 | 27 | N/R |
| Velcheti et al, 201746 | II | Lenvatinib | Multi-kinase inhibitor | 25 | 16 | 7.3 | N/R | 92 | 20 |
| Subbiah et al.51 | Vandetanib +Everolimus | Multi-kinase inhibitor + mTOR inhibitor | 13 | 54 | 4.4 | N/R | N/R | N/R | |
| Oxnard et al, 201853 (LIBRETTO-001) | I/II | LOXO-292 | Selective RET inhibitor | 38 | 68 | N/R | N/R | 4.8 | 0 |
| Subbiah et al, 201854,55 (ARROW) | I | BLU-667 | Selective RET inhibitor | 19 | 50 | N/R | N/R | 6.9 | N/R |
| Drilon et al, 201858 | I/Ib | RXDX-105 | Selective RET inhibitor | 40 | 19 | N/R | N/R | 35 | 16 |
Abbreviation: N/R, not reported.